Literature DB >> 28980404

Preventive and therapeutic potential of ascorbic acid in neurodegenerative diseases.

Morgana Moretti1, Daiane Bittencourt Fraga1, Ana Lúcia S Rodrigues1.   

Abstract

In this review, we summarize the involvement of ascorbic acid in neurodegenerative diseases by presenting available evidence on the behavioral and biochemical effects of this compound in animal models of neurodegeneration as well as the use of ascorbic acid as a therapeutic approach to alleviate neurodegenerative progression in clinical studies. Ascorbate, a reduced form of vitamin C, has gained interest for its multiple functions and mechanisms of action, contributing to the homeostasis of normal tissues and organs as well as to tissue regeneration. In the brain, ascorbate exerts neuromodulatory functions and scavenges reactive oxygen species generated during synaptic activity and neuronal metabolism. These are important properties as redox imbalance and abnormal protein aggregation constitute central mechanisms implicated in the pathogenesis of neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's diseases, multiple sclerosis, and amyotrophic lateral sclerosis. Indeed, several studies have indicated an association between low serum ascorbate concentrations and neurodegeneration. Moreover, ascorbic acid is a suitable candidate for supplying either antioxidant defense or modulation of neuronal and astrocytic metabolism under neurodegenerative conditions. Ascorbic acid acts mainly by decreasing oxidative stress and reducing the formation of protein aggregates, which may contribute to the reduction of cognitive and/or motor impairments observed in neurodegenerative processes. Although several studies support a possible role of ascorbic acid administration against neurodegeneration, more researches are essential to substantiate the existing results and accelerate the knowledge in this field.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  ascorbic acid; central nervous system; neurodegeneration; neuromodulation

Mesh:

Substances:

Year:  2017        PMID: 28980404      PMCID: PMC6492647          DOI: 10.1111/cns.12767

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  64 in total

1.  Intakes of carotenoids, vitamin C, and vitamin E and MS risk among two large cohorts of women.

Authors:  S M Zhang; M A Hernán; M J Olek; D Spiegelman; W C Willett; A Ascherio
Journal:  Neurology       Date:  2001-07-10       Impact factor: 9.910

Review 2.  A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness.

Authors:  Michael Maes; Piotr Galecki; Yong Seun Chang; Michael Berk
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-05-12       Impact factor: 5.067

3.  Effect of supplementation of vitamin E and vitamin C on brain acetylcholinesterase activity and neurotransmitter levels in rats treated with scopolamine, an inducer of dementia.

Authors:  L Lee; S A Kang; H O Lee; B H Lee; I K Jung; J E Lee; Y S Hoe
Journal:  J Nutr Sci Vitaminol (Tokyo)       Date:  2001-10       Impact factor: 2.000

4.  Macrophage uptake and recycling of ascorbic acid: response to activation by lipopolysaccharide.

Authors:  James M May; Junjun Huang; Zhi-Chao Qu
Journal:  Free Radic Biol Med       Date:  2005-08-19       Impact factor: 7.376

5.  Ameliorative effects of vitamin C on short-term sensorimotor and cognitive changes induced by acute chlorpyrifos exposure in Wistar rats.

Authors:  Suleiman F Ambali; Sherifat B Idris; Charles Onukak; Mufta'u Shittu; Joseph O Ayo
Journal:  Toxicol Ind Health       Date:  2010-06-16       Impact factor: 2.273

6.  Ascorbic acid prevents beta-amyloid-induced intracellular calcium increase and cell death in PC12 cells.

Authors:  S Yallampalli; M A Micci; G Taglialatela
Journal:  Neurosci Lett       Date:  1998-07-24       Impact factor: 3.046

7.  Serum levels of ascorbic acid (vitamin C) in patients with Parkinson's disease.

Authors:  P Férnandez-Calle; F J Jiménez-Jiménez; J A Molina; F Cabrera-Valdivia; A Vázquez; D García Urra; F Bermejo; M Cruz Matallana; R Codoceo
Journal:  J Neurol Sci       Date:  1993-08       Impact factor: 3.181

Review 8.  A vitamin as neuromodulator: ascorbate release into the extracellular fluid of the brain regulates dopaminergic and glutamatergic transmission.

Authors:  G V Rebec; R C Pierce
Journal:  Prog Neurobiol       Date:  1994-08       Impact factor: 11.685

9.  Concentrations of vitamins A, C and E in elderly patients with Parkinson's disease.

Authors:  D King; J R Playfer; N B Roberts
Journal:  Postgrad Med J       Date:  1992-08       Impact factor: 2.401

10.  A failure in energy metabolism and antioxidant uptake precede symptoms of Huntington's disease in mice.

Authors:  Aníbal I Acuña; Magdalena Esparza; Carlos Kramm; Felipe A Beltrán; Alejandra V Parra; Carlos Cepeda; Carlos A Toro; René L Vidal; Claudio Hetz; Ilona I Concha; Sebastián Brauchi; Michael S Levine; Maite A Castro
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  18 in total

Review 1.  Corticostriatal network dysfunction in Huntington's disease: Deficits in neural processing, glutamate transport, and ascorbate release.

Authors:  George V Rebec
Journal:  CNS Neurosci Ther       Date:  2018-02-21       Impact factor: 5.243

2.  Microporous carbon in the selective electro-oxidation of molecular biomarkers: uric acid, ascorbic acid, and dopamine.

Authors:  Tidapa Rattanaumpa; Santi Maensiri; Kamonwad Ngamchuea
Journal:  RSC Adv       Date:  2022-06-27       Impact factor: 4.036

3.  Druggable transcriptomic pathways revealed in Parkinson's patient-derived midbrain neurons.

Authors:  Mark van den Hurk; Shong Lau; Maria C Marchetto; Jerome Mertens; Shani Stern; Olga Corti; Alexis Brice; Beate Winner; Jürgen Winkler; Fred H Gage; Cedric Bardy
Journal:  NPJ Parkinsons Dis       Date:  2022-10-18

Review 4.  Lipoic Acid and Other Antioxidants as Therapies for Multiple Sclerosis.

Authors:  Carin Waslo; Dennis Bourdette; Nora Gray; Kirsten Wright; Rebecca Spain
Journal:  Curr Treat Options Neurol       Date:  2019-05-06       Impact factor: 3.598

Review 5.  Preventive and therapeutic potential of ascorbic acid in neurodegenerative diseases.

Authors:  Morgana Moretti; Daiane Bittencourt Fraga; Ana Lúcia S Rodrigues
Journal:  CNS Neurosci Ther       Date:  2017-10-04       Impact factor: 5.243

6.  Chronic Treatment of Ascorbic Acid Leads to Age-Dependent Neuroprotection against Oxidative Injury in Hippocampal Slice Cultures.

Authors:  Kyung Hee Lee; Un Jeng Kim; Myeounghoon Cha; Bae Hwan Lee
Journal:  Int J Mol Sci       Date:  2021-02-05       Impact factor: 5.923

7.  Oxidative Stress and Inflammation Interdependence in Multiple Sclerosis.

Authors:  Rodica Padureanu; Carmen Valeria Albu; Radu Razvan Mititelu; Manuela Violeta Bacanoiu; Anca Oana Docea; Daniela Calina; Vlad Padureanu; Gabriela Olaru; Raluca Elena Sandu; Ramona Denise Malin; Ana-Maria Buga
Journal:  J Clin Med       Date:  2019-11-01       Impact factor: 4.241

8.  NXP031 Improves Cognitive Impairment in a Chronic Cerebral Hypoperfusion-Induced Vascular Dementia Rat Model through Nrf2 Signaling.

Authors:  Jae-Min Lee; Joo-Hee Lee; Min-Kyung Song; Youn-Jung Kim
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

Review 9.  On the physiological and cellular homeostasis of ascorbate.

Authors:  Magdalena Przybyło; Marek Langner
Journal:  Cell Mol Biol Lett       Date:  2020-05-29       Impact factor: 5.787

10.  Oral ascorbic acid 2-glucoside prevents coordination disorder induced via laser-induced shock waves in rat brain.

Authors:  Takaaki Maekawa; Takahiro Uchida; Yuka Nakata-Horiuchi; Hiroaki Kobayashi; Satoko Kawauchi; Manabu Kinoshita; Daizoh Saitoh; Shunichi Sato
Journal:  PLoS One       Date:  2020-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.